Cycle on Sep 21, 2026

I'll start by reviewing the topic's open threads and existing notes to understand where the research stands.

I have a clear picture of the topic's state. Key open watches to check this cycle: the Novo v. Lilly preliminary injunction ruling (fire date Aug 31 — past due), Viking's VK2735 Phase 1 maintenance data (due 3Q26), and zenagamtide/petrelintide Phase 3 initiations (due ~Oct 1). Let me search for the latest news.

I have good leads. Now let me dig into the specific watch items: the Novo v. Lilly injunction ruling, Viking's VK2735 data, and the Novo CEO strategy comments.

The injunction ruling hasn't landed yet (motion argued Aug 17, still pending per recent coverage), and Viking's maintenance data is still imminent. Let me check the NAION vision-loss litigation development and the Novo CEO strategy comments — both look fresh.

Two important developments: the NAION vision-loss MDL is growing (216 cases as of Sep 1), and Novo has a capital markets day TODAY (Sep 21). Let me check what's happening at that event and the remaining watch items.

Novo's Capital Markets Day is happening today, and shares fell ~7.7% on the outlook. Let me get the details from the press release and coverage.

The CMD details are solid — Novo set 2030 ambitions but shares fell 7.7% on the outlook. Now let me verify the NAION litigation numbers and check the remaining watch items (zenagamtide/petrelintide Phase 3 starts).

MDL numbers confirmed: 4,022 GI-injury cases and 216 NAION cases as of Sep 1, with a Rule 702 hearing this week. Now let me get the fresh industry coverage and the gray-market enforcement update.

The ABC settlement is from May — already covered previously, so I'll skip it. Let me get the latest oral GLP-1 prescription tracker data and check for any insurance/policy news this week.

Strong data across the board. Let me try to confirm the market reaction to Novo's CMD and get the Medicare Bridge Program details (it's reportedly "far exceeding" expectations).

I have all the evidence needed. My next step: write the five findings (two new subjects, three updates to existing slugs), then register the new watch and thread, then finish the cycle.

Two new findings saved. The third call was malformed — let me now write the three updates to existing slugs properly.

All five findings are saved. Now let me register the forward-looking items: a watch on the Daubert ruling (the key litigation catalyst) and a thread to digest the full CMD materials next cycle.

The watch registered. The thread kind "investigation" was rejected — let me retry with kind "question".

Cycle complete. Here's what this research cycle found: ## This cycle's findings (Sep 14–21, 2026) **1. Novo's strategic reset — rebrand + Capital Markets Day (new finding)** Novo rebranded to "Novo" with "The Novo Way" under CEO Doustdar, and at today's CMD set 2030 ambitions: >5 multi-blockbuster launches, >150b DKK ($23B) risk-adjusted pipeline sales by 2035, 10x oral GLP-1 capacity, >60M patients served. The market balked — **shares fell as much as 7.7%** because targets were relative ("in line with peers") and back-loaded rather than hard guidance. **2. GLP-1 litigation overhang building (new finding)** MDL-3094 (GI injuries) hit **4,022 pending cases**, with the pivotal Rule 702 Daubert hearing held Sep 14–18. The NAION vision-loss docket (MDL-3163) doubled from 110 to **216 cases in three months**, plus 90+ NJ state suits. Novo's CMO denies any causation signal; Australia added label warnings in August. **3. Oral GLP-1 war update** — Foundayo now claims **>30% of new oral obesity starts** (up from 21.5% in late August), while the Wegovy pill holds a 3.4x volume lead (~161K vs ~47K weekly scripts). Critically, orals are *broadening* the market: total GLP-1 scripts +5.4% vs -6.8% a year ago. **4. Medicare Bridge exceeding expectations** — Walgreens and CVS each filled 100K+ scripts; ~600K seniors enrolled. But Walgreens warns of a "natural plateau" and a post-2027 coverage cliff. **5. Employer coverage squeeze** — employer costs projected +9.5% in 2027 driven partly by GLP-1s; Lilly admits "coverage remains the main constraint, not demand" and is pushing its Employer Connect program as payers build cost-containment products. **Watch registered:** Daubert ruling in MDL-3094 (the litigation's make-or-break gatekeeper). **Thread opened:** digest full CMD materials next cycle. No existing watches fired — the Novo v. Lilly injunction ruling, Viking's maintenance data, and the CagriSema FDA decision all remain pending.

The research cycle is complete. Five findings were persisted (two new subjects, three updates to existing slugs), one new watch registered on the MDL-3094 Daubert ruling, and one thread opened to digest Novo's CMD materials in detail next cycle.